These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 16839637)

  • 1. Identification of two amino acid residues on Ebola virus glycoprotein 1 critical for cell entry.
    Mpanju OM; Towner JS; Dover JE; Nichol ST; Wilson CA
    Virus Res; 2006 Nov; 121(2):205-14. PubMed ID: 16839637
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Involvement of viral envelope GP2 in Ebola virus entry into cells expressing the macrophage galactose-type C-type lectin.
    Usami K; Matsuno K; Igarashi M; Denda-Nagai K; Takada A; Irimura T
    Biochem Biophys Res Commun; 2011 Apr; 407(1):74-8. PubMed ID: 21362405
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influences of glycosylation on antigenicity, immunogenicity, and protective efficacy of ebola virus GP DNA vaccines.
    Dowling W; Thompson E; Badger C; Mellquist JL; Garrison AR; Smith JM; Paragas J; Hogan RJ; Schmaljohn C
    J Virol; 2007 Feb; 81(4):1821-37. PubMed ID: 17151111
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of a cAdVax-based bivalent ebola virus vaccine that induces immune responses against both the Sudan and Zaire species of Ebola virus.
    Wang D; Raja NU; Trubey CM; Juompan LY; Luo M; Woraratanadharm J; Deitz SB; Yu H; Swain BM; Moore KM; Pratt WD; Hart MK; Dong JY
    J Virol; 2006 Mar; 80(6):2738-46. PubMed ID: 16501083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive analysis of ebola virus GP1 in viral entry.
    Manicassamy B; Wang J; Jiang H; Rong L
    J Virol; 2005 Apr; 79(8):4793-805. PubMed ID: 15795265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of the Ebola virus glycoprotein as the main viral determinant of vascular cell cytotoxicity and injury.
    Yang ZY; Duckers HJ; Sullivan NJ; Sanchez A; Nabel EG; Nabel GJ
    Nat Med; 2000 Aug; 6(8):886-9. PubMed ID: 10932225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phenylalanines at positions 88 and 159 of Ebolavirus envelope glycoprotein differentially impact envelope function.
    Ou W; King H; Delisle J; Shi D; Wilson CA
    Virology; 2010 Jan; 396(1):135-42. PubMed ID: 19906395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of Marburg virus glycoprotein in viral entry.
    Manicassamy B; Wang J; Rumschlag E; Tymen S; Volchkova V; Volchkov V; Rong L
    Virology; 2007 Feb; 358(1):79-88. PubMed ID: 16989883
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Release of viral glycoproteins during Ebola virus infection.
    Volchkov VE; Volchkova VA; Slenczka W; Klenk HD; Feldmann H
    Virology; 1998 May; 245(1):110-9. PubMed ID: 9614872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complete genome sequence of an Ebola virus (Sudan species) responsible for a 2000 outbreak of human disease in Uganda.
    Sanchez A; Rollin PE
    Virus Res; 2005 Oct; 113(1):16-25. PubMed ID: 16139097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Naturally Occurring Polymorphism in the Base of Sudan Virus Glycoprotein Decreases Glycoprotein Stability in a Species-Dependent Manner.
    Lennemann NJ; Dillard J; Ruggio N; Cooney AL; Schaack GA; Davey RA; Maury W
    J Virol; 2021 Aug; 95(18):e0107321. PubMed ID: 34232742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single and multiple deletions in the transmembrane domain of the Sindbis virus E2 glycoprotein identify a region critical for normal virus growth.
    Whitehurst CB; Willis JH; Sinodis CN; Hernandez R; Brown DT
    Virology; 2006 Mar; 347(1):199-207. PubMed ID: 16387341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current knowledge on lower virulence of Reston Ebola virus (in French: Connaissances actuelles sur la moindre virulence du virus Ebola Reston).
    Morikawa S; Saijo M; Kurane I
    Comp Immunol Microbiol Infect Dis; 2007 Sep; 30(5-6):391-8. PubMed ID: 17610952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chimpanzee adenovirus vaccine protects against Zaire Ebola virus.
    Kobinger GP; Feldmann H; Zhi Y; Schumer G; Gao G; Feldmann F; Jones S; Wilson JM
    Virology; 2006 Mar; 346(2):394-401. PubMed ID: 16356525
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulation of virion incorporation of Ebolavirus glycoprotein: effects on attachment, cellular entry and neutralization.
    Marzi A; Wegele A; Pöhlmann S
    Virology; 2006 Sep; 352(2):345-56. PubMed ID: 16777170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of the receptor-binding domain of Ebola glycoprotein in viral entry.
    Wang J; Manicassamy B; Caffrey M; Rong L
    Virol Sin; 2011 Jun; 26(3):156-70. PubMed ID: 21667336
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spontaneous Mutation at Amino Acid 544 of the Ebola Virus Glycoprotein Potentiates Virus Entry and Selection in Tissue Culture.
    Ruedas JB; Ladner JT; Ettinger CR; Gummuluru S; Palacios G; Connor JH
    J Virol; 2017 Aug; 91(15):. PubMed ID: 28539437
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of rVSVΔG-ZEBOV-GP glycoproteins using automated capillary western blotting.
    Minsker K; Rustandi RR; Ha S; Loughney JW
    Vaccine; 2020 Oct; 38(45):7166-7174. PubMed ID: 32951937
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro evaluation of cyanovirin-N antiviral activity, by use of lentiviral vectors pseudotyped with filovirus envelope glycoproteins.
    Barrientos LG; Lasala F; Otero JR; Sanchez A; Delgado R
    J Infect Dis; 2004 Apr; 189(8):1440-3. PubMed ID: 15073681
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cellular entry of ebola virus involves uptake by a macropinocytosis-like mechanism and subsequent trafficking through early and late endosomes.
    Saeed MF; Kolokoltsov AA; Albrecht T; Davey RA
    PLoS Pathog; 2010 Sep; 6(9):e1001110. PubMed ID: 20862315
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.